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Summary. Lysyl oxidase (LOX) is the extracellular 
enzyme that initiates the main pathway of collagen and 
elastin cross-linking. LOX has also been correlated with 
the ras  recision gene, a putative tumour suppressor 
isolated from revertants of ras-transformed fibroblasts. 
The present study investigates the potential correlation 
of LOX-dependent matrix protein cross-linking in the 
stromal reaction of lung carcinomas, with reference to 
the architecture of the main stromal reactions 
accompanying the neoplastic breast tissues. A strong 
LOX expression was associated with the hypertrophic 
scar-like stromal reaction found at the front of tumour 
progression in squamous carcinomas, adenocarcinomas, 
large cell carcinomas, or at sites of initial extense in 
bronchiolo-alveolar carcinomas. In contrast, little or no 
LOX expression was found within the stromal reaction 
of invasive carcinomas, small cell carcinomas, and 
neuro-endocrine carcinomas. The significance of LOX 
expression and of the stromal reaction are discussed, in 
light of data that associate LOX expression with tumours 
displaying a rather good prognosis. 
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Introduction 
The extracellular matrix (ECM) represents the 
particular environment for tumour cell expansion and 
plays a crucial role in cell differentiation and tumour 
morphogenesis (Martinez-Hernandez, 1988). The 
significance of the stromal reaction in cancer has been 
interpreted either as a limitation mechanism against 
tumour progression by the formation of a physical 
barrier with limitation of angiogenesis and increase of 
metalloprotease inhibitors, or as a promoting mechanism 
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for tumour growth with the loosening of the matrix by 
proteases and angiogenesis (Lagac6 et al., 1985). We 
have recently reported that the early development of a 
cross-linked matrix rich in lysyl oxidase (LOX) around 
ductal breast carcinomas may represent a possible host 
defense mechanism in breast tumours, whereas the 
synchronous stromal reaction of invasive tumours 
lacking LOX may favor tumour dispersion (Peyrol et al. 
1997). 
LOX is an extracellular amine oxidase which 
initiates collagen and elastin cross-linking (Srnith- 
Mungo and Kagan, 1998). LOX belongs to a new family 
of four members, together with the newly discovered 
LOXLl, LOXL2, and LOXL3 (Kenyon et al., 1993; 
Saito et al., 1997; Decitre et al., 1998; Jang et al., 1999; 
Jourdan Le Saux et al., 1999). Though the involvement 
of LOX in collagen cross-linking has been well 
documented, with the three other enzymes, only LOXLl 
protein expression has been studied and associated with 
extracellular matrix remodelling (Decitre et al., 1998). 
The LOX gene has also been correlated with the ras 
recision gene (rrg), a putative tumour suppressor 
isolated from non-tumourigenic revertants of ras- 
transformed fibroblasts (Kenyon et al., 1991). It has 
been suggested that this tumour suppressor activity is 
due to the formation of extracellular cross-linked 
collagen modulating the cell phenotype (Contente et al., 
1990). This hypothesis is consistent with the early 
development of a LOX-rich cross-linked matrix 
surrounding ductal breast carcinomas (Peyrol et al., 
1997). However, the suppressor activity of LOX may 
also be accounted for by an intracellular or intranuclear 
localization (Wakasaki and Ooshima, 1990; Li et al., 
1997), as the microinjection of recombinant LOX blocks 
the p21-Ha-ras  induced oncogenic phenotype of 
Xenopus laevis oocytes (Di Donato et al., 1997). The 
steady state level of LOX transcription is high in 
fibrocompetent cells (myofibroblasts and smooth muscle 
cells) and low in malignantly transformed cells, in c-H- 
ras- or v-Ki-ras-transformed cells, or in metastatis- 
derived mouse prostate cancer cell lines (Contente et al., 
1990; Smith-Mungo and Kagan, 1998; Reynaud et al., 








